Navigation Links
New Contact Lenses Could Improve Glaucoma Treatment

They come loaded with vitamin E, to help more medicine get to cornea, researcher says

WEDNESDAY, March 24 (HealthDay News) -- A team of researchers has created special contact lenses for glaucoma patients that come loaded with vitamin E, using a design that could essentially lengthen the amount of time a medication bathes an afflicted eye.

This strategy could reduce the significant waste of medication that happens with traditional eye drops, but so far the concept has only been tested in beagles.

"Currently, the way we deliver medication to the eye is very bad and very ineffective," said study author Anuj Chauhan, an associate professor in the department of chemical engineering at the University of Florida in Gainesville. "And this approach is wonderful because it delivers drugs for a long period of time."

Chauhan and his colleagues are to present their findings Wednesday at the American Chemical Society annual meeting in San Francisco.

According to the Glaucoma Research Foundation, glaucoma starts as a symptom-less disease that, through damage to the optic nerve, can ultimately rob a patient of his or her sight. The disease accounts for approximately 9 percent to 12 percent of all blindness in the United States, and the World Health Organization notes that it is the second leading cause of blindness worldwide.

There is no cure for the estimated 4 million Americans who have the disease, and once vision is lost, it cannot be restored. However, treatments -- including medicine and surgery -- do slow down or halt disease progression.

Vitamin E is thought to aid vision because of its antioxidant capacities, and several studies have already explored the notion that it could help combat glaucoma when used in conjunction with prescription drugs.

The current research focused on contact lenses that can be worn for up to a month.

The authors note that their study has already revealed that contacts pre-loaded with vitamin E can extend drug-delivery duration by upwards of 100 times when compared with regular commercial lenses. Delivery of medications via eye drops only exposes the eye to two to five minutes of treatment, they added.

Human trials to test the approach are still one to two years away, Chauhan said. But he added that, if successful, this drug-delivery method could have multiple applications beyond the goal of improving glaucoma treatment.

"This could have significant benefits for several millions of patients, from both a therapeutic angle and a prevention angle," he said. "Because not only could it provide better drug relief for glaucoma, but it could potentially address a number of other eye diseases, such as cataracts and dry eye. And the neutroceuticals of vitamin E also block UV light exposure."

"But what will actually work out in the future only time will tell," Chauhan cautioned.

Meanwhile, Dr. Alfred Sommer, a professor of ophthalmology and dean emeritus at the Bloomberg School of Public Health at Johns Hopkins University in Baltimore, expressed some reservations about the approach.

"A delivery mechanism to essentially bathe the eye in slow and continuous medication to target a whole range of diseases from macular degeneration to glaucoma has been a holy grail for ophthalmology for many years," he noted. "But by and large the efforts to do this have not proven successful, although it would certainly be nice to have."

"But since the most effective glaucoma drops we have today you only have to put in once a day, the question then is, would people really put a contact lens in their eye when they don't really otherwise use contacts?" Sommer asked. "That is speculative, particularly when we strongly advise contact lens wearers never to wear a lens overnight. So, it's not immediately apparent to me what the advantages would be for glaucoma."

At the same meeting, a research team out of Iowa State University is scheduled to report Wednesday on a new technology that might be able to catch glaucoma in its pre-symptomatic, early stages.

Led by Iowa State assistant professor Chenxu Yu, the team said they believe they are on the verge of a diagnostic "breakthrough" with the aid of infrared laser light -- via a method called "Raman spectroscopy" -- that shines through the eye's pupil to take a "snapshot" of the retina. They hope the high-tech picture could one day be used to identify biochemical signs of glaucoma in its infancy.

More information

For more on glaucoma, visit the Glaucoma Research Foundation.

SOURCES: Anuj Chauhan, Ph.D., associate professor, department of chemical engineering, and director, graduate programs, University of Florida, Gainesville; Alfred Sommer, M.D., professor, ophthalmology, and dean emeritus, Bloomberg School of Public Health, Johns Hopkins University, Baltimore; March 24, 2010, presentation, American Chemical Society annual meeting, San Francisco

Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Breakthrough Invention: New Device Makes Contact Lenses and Eye Drops Easier Than Ever Before
2. Contact Lenses Often Prescribed For Infants With Serious Eye Problems
3. Contact Center Compliance Launches New Sales Agent Productivity Tool: "SmartBlock (TM)"
4. ICMI Announces the ACCE 2010 Conference & Expo, Brings Contact Professionals Together to Improve Contact Center Performance
5. Contact Dermatitis Can Be Irritating, Especially When the Cause is a Mystery
6. Online Tool Created to Contact Vatican Officials: Why Are American Bishops Allowed to Defy the Popes Words Concerning Child Killing and the Eucharist?
7. Ophthonix Launches iZon(R) SL(TM) Polarized Lenses
8. The Flag Company, Inc.'s Recently Released “Feel Good” Light Lenses Grows Into Its Own Website
9. The Eye Institute of Utah Hosts World Renowned Cataract Surgeons: In Economically Trying Times, Nine Fortunate Patients Receive State of the Art Cataract Lenses
10. Road mapping could be key to curing TB
11. What if You Could Help to Influence the NYC Taxi of Tomorrow?
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, I ... Bronx, N.Y. “I thought there had to be a convenient and comfortable way to ... The PROTECTOR enables disabled individuals to safely travel during cold or inclement weather. In ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care ... disease. The Periwinkle Pioneers, nominated by the public, will receive special recognition throughout ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... philanthropic seniors, is resulting in a way for homeless people to have a ... have launched a new initiative whereby they are repurposing plastic bags into sleeping ...
(Date:11/25/2015)... ... November 25, 2015 , ... Since its launch in 2012, ... adult stem cell therapies to patients with chronic degenerative medical conditions. Now, the ... Registered Trademark (RTM). , Organizations are required to hold a registered trademark in ...
(Date:11/24/2015)... ... November 25, 2015 , ... Genesis Chiropractic Software ... software creates an agreement between the practice owner and the patient that automatically ... notification, and projections. Click here to learn more. , ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... FRANCISCO , Nov. 24, 2015  Thanks to ... Dignity Health St. Mary,s Medical Center,s Sister Diane Grassilli ... breast imaging capabilities in San Francisco ... an anonymous friend, stepped forward with a gift of ... for Breast Digital Mammography with Tomosynthesis and Whole Breast ...
(Date:11/24/2015)... Colo. , Nov. 24, 2015  Array ... that its Chief Executive Officer, Ron Squarer ... Healthcare Conference in New York.  The public is ... webcast on the Array BioPharma website.Event:Piper Jaffray Annual ... , Wednesday, December 2, 2015Time:1:30 p.m. Eastern Time ...
(Date:11/24/2015)... HOUSTON, TX and VANCOUVER, Nov. 24, 2015 /PRNewswire/ ... EPI; NASDAQ: EPIX ) announced today that the ... clinical study of EPI-506 as a treatment for metastatic ... States and Canada.  --> ... --> In the Phase 1/2 clinical trial, ...
Breaking Medicine Technology: